These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20222179)

  • 1. Rituximab maintenance for follicular lymphoma.
    Vidal L; Gafter-Gvili A; Shpilberg O
    Nat Rev Clin Oncol; 2010 Mar; 7(3):1; author reply 1. PubMed ID: 20222179
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab maintenance therapy in follicular lymphoma comes of age.
    Hiddemann W
    Leuk Res; 2006 Mar; 30 Suppl 1():S1-2. PubMed ID: 16750672
    [No Abstract]   [Full Text] [Related]  

  • 3. Hodgkin disease subsequent to follicular lymphoma on maintenance rituximab.
    Scaramucci L; Perrotti A; Niscola P; Fratoni S; Palombi M; Piccioni D; Cupelli L; Tendas A; Dentamaro T; Del Poeta G; De Fabritiis P
    Leuk Lymphoma; 2007 Sep; 48(9):1878-80. PubMed ID: 17786731
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab chemotherapy regimens for treating advanced follicular lymphoma evaluated in new study.
    Askeland G
    Expert Rev Clin Immunol; 2013 May; 9(5):402. PubMed ID: 23772446
    [No Abstract]   [Full Text] [Related]  

  • 5. Rituximab maintenance therapy in indolent NHL: a clinical review.
    Buske C; Hiddemann W
    Leuk Res; 2006 Mar; 30 Suppl 1():S11-5. PubMed ID: 16750673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma: profile report.
    Croxtall JD
    BioDrugs; 2011 Oct; 25(5):329-31. PubMed ID: 21942917
    [No Abstract]   [Full Text] [Related]  

  • 7. What is the role of maintenance rituximab in follicular NHL?
    Maloney DG
    Oncology (Williston Park); 2008 Jan; 22(1):20-6; discussion 26, 29, 33-4. PubMed ID: 18251281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary duodenal follicular lymphoma successfully treated with rituximab.
    Aguiar-Bujanda D; Quiñones-Morales I; Camacho-Galán R; Llorca-Martínez I; Rivero-Vera JC; Bohn-Sarmiento U; Aguiar-Morales J
    Clin Transl Oncol; 2007 Jul; 9(7):471-2. PubMed ID: 17652063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in gene expression patterns in follicular lymphoma and the response to rituximab.
    Bohen SP; Troyanskaya OG; Alter O; Warnke R; Botstein D; Brown PO; Levy R
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1926-30. PubMed ID: 12571354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab by subcutaneous route.
    Solal-Celigny P
    Expert Rev Hematol; 2015 Apr; 8(2):147-53. PubMed ID: 25749209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenance.
    Roy R; Gordon LI
    J Natl Compr Canc Netw; 2011 May; 9(5):563-71. PubMed ID: 21550969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance rituximab should be considered for patients with follicular lymphoma.
    Barr PM
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
    [No Abstract]   [Full Text] [Related]  

  • 13. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.
    Racila E; Link BK; Weng WK; Witzig TE; Ansell S; Maurer MJ; Huang J; Dahle C; Halwani A; Levy R; Weiner GJ
    Clin Cancer Res; 2008 Oct; 14(20):6697-703. PubMed ID: 18927313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
    Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab maintenance therapy for follicular lymphoma.
    Haines I
    Lancet; 2011 Apr; 377(9772):1151; author reply 1151-2. PubMed ID: 21459205
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab maintenance versus radio-immunotherapy consolidation in first remission follicular non-Hodgkin lymphoma.
    Hagenbeek A
    Transfus Apher Sci; 2013 Aug; 49(1):43. PubMed ID: 23932512
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab for follicular non-Hodgkin lymphoma.
    Gajraj E; Chung H; Longson C; Stevens A
    Lancet Oncol; 2008 Apr; 9(4):320-1. PubMed ID: 18405852
    [No Abstract]   [Full Text] [Related]  

  • 18. Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma.
    Sanchez-Gonzalez B; Gimeno E; Garcia-Pallarols F; Ancochea A; Salar A
    Leuk Lymphoma; 2014 Oct; 55(10):2384-6. PubMed ID: 24601815
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation.
    Wake B; Hyde C; Bryan S; Barton P; Song F; Fry-Smith A; Davenport C
    Health Technol Assess; 2002; 6(3):1-85. PubMed ID: 12022936
    [No Abstract]   [Full Text] [Related]  

  • 20. Considerations with newer regimens for indolent non-Hodgkin lymphoma.
    Rummel M
    Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S128-36. PubMed ID: 18952543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.